Efficiency and safety of preoperative Tranexamic acid in reducing perioperative blood loss in elective cesarean sectio

Phase 4

Completed

• Conditions: blood loss during and after cesarean section; Reproductive Health and Childbirth - Childbirth and postnatal care

• Registration Number: ACTRN12615000312549
• Lead Sponsor: Ahmed Maged

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

full-term singleton pregnancies underwent elective lower segment caesarean section

Exclusion Criteria

1.prolonged CS (> 90 min according to anesthetic record), 2.anemic patients (Hb < 9 gm %),
3.presence of maternal medical disorder (e.g. cardiac, renal, hepatic & coagulopathies) or
4.history of thrombo-embolic events.
5.known allergy to TA.
6.Patients with increased risk for obstetric hemorrhage (e.g. antepartum hemorrhage, abnormal placentation, previous history of uterine atony & postpartum hemorrhage, polyhydramnios & uterine fibroids).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
estimated blood loss (EBL) during and after Cesarean section<br>Estimated blood loss was calculated according to the following formula:<br>EBL = EBV × Preop Hematocrit - Postop Hematocrit /Preop Hematocrit <br>EBL: estimated blood loss<br>EBV: estimated blood volume (ml) = weight (kg) x 85<br>[24 hours after Cesarean section]

Secondary Outcome Measures

Name	Time	Method
1. postoperative hemoglobin, serum assay<br>[up to 4 weeks after surgery];postoperative hematocrit, serum assay[4 weeks after CS];platelet count , serum assay [4 weeks after CS];needed postoperative ecbolics. needed drugs administered intramuscular[24 hours after CS]